8YY — Biolidics Income Statement
0.000.00%
Last trade - 00:00
- SG$8.94m
- SG$10.78m
- SG$1.32m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.44 | 8.91 | 2.31 | 2.49 | 1.31 |
Cost of Revenue | |||||
Gross Profit | 0.966 | 3.44 | 0.483 | 1.16 | 0.721 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 6.24 | 13.5 | 8.15 | 12.2 | 3.69 |
Operating Profit | -4.8 | -4.56 | -5.83 | -9.68 | -2.38 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -4.81 | -4.68 | -6.04 | -9.85 | -2.49 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.81 | -4.65 | -5.98 | -9.37 | -2.49 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.81 | -4.65 | -5.98 | -9.37 | -2.49 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.81 | -4.65 | -5.98 | -9.37 | -2.49 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.018 | -0.018 | -0.021 | -0.024 | -0.004 |